Tag: Kidney Disease
-
Kidney Disease Advocate Honoured in New Year Honours for Nutrition-led Care
Acknowledging a career focused on kidney disease A health professional from Somerville has been named an Officer of the New Year Honours for a career dedicated to improving kidney disease care. The recognition highlights a life spent tackling one of medicine’s most complex challenges, with a particular focus on how nutrition can influence outcomes across…
-
Lyn Lloyd Honoured in New Year Honours for Kidney Nutrition Work
Introduction: A career shaped by kidney disease In the medical field, few areas demand as much cross-disciplinary knowledge as kidney disease. A dedicated health professional from Somerville has been recognised in the New Year Honours for her work in this challenging arena. Lyn Lloyd’s career has been driven by a deep interest in how nutrition…
-
Career Focused on Kidney Disease Acknowledged
A career shaped by kidney disease and nutrition In the New Year Honours, a dedicated health professional from Somerville has been recognised for a career that blends clinical expertise, patient care, and a focus on nutrition’s critical role in kidney disease. Lyn Lloyd’s work spans early detection, treatment pathways, and practical dietary guidance, underscoring how…
-
Daily Fish Oil Slashes Heart Risks in Dialysis Patients, PISCES Trial Finds
New evidence links fish oil to reduced heart risk for dialysis patients A large, multinational study has found that daily fish oil supplementation may significantly cut the risk of serious heart events among people undergoing dialysis. The PISCES trial followed 1,228 participants across 26 sites in Australia and Canada, tracking outcomes over a period designed…
-
NHS Urges Immediate GPVisit: Dapagliflozin Warning If You Have Three Symptoms
What the NHS warning means fordapagliflozin users The NHS has issued a clear safety warning for people taking the diabetes drug dapagliflozin, which is also prescribed for heart failure and chronic kidney disease. The warning emphasizes that patients should contact their GP immediately if they experience any combination of three specific symptoms. While dapagliflozin offers…
-
Renalys Pharma Reports Positive Phase III Topline Results for Sparsentan in Japanese IgA Nephropathy Patients
Positive topline results in Japanese IgA nephropathy trial Renalys Pharma announced positive topline data from a Phase III study evaluating sparsentan in Japanese patients with IgA nephropathy (IgAN). The trial enrolled 35 participants and was designed to assess the efficacy and safety of sparsentan, a dual-acting agent targeting both the endothelin and angiotensin receptor pathways,…
-
Sparsentan Delivers Positive Phase 3 Results in Japanese IgA Nephropathy
Overview: sparsentan earns positive topline data in Japanese IgA nephropathy Renalys Pharmaceutical Co. announced encouraging topline results from a Phase 3 study evaluating sparsentan, a dual-acting agent, in Japanese patients with IgA nephropathy (IgAN). The trial focused on the safety and efficacy of sparsentan in a specific, well-defined cohort (N=35) and sought to determine whether…
-
Sobi to Unveil One-Year Pegcetacoplan Data for C3G, IC-MPGN and NASP at ASN Kidney Week 2025
Overview: Sobi to Share New Pegcetacoplan Data at ASN Kidney Week 2025 Sobi, a global biopharmaceutical company focused on rare diseases, has announced that new data on pegcetacoplan will be presented at ASN Kidney Week 2025, taking place from November 5–9. The presentations will explore one-year efficacy data for pegcetacoplan in C3 glomerulopathy (C3G) and…
-
SDMA as a Predictor of Cardiovascular Risk in CKD Patients
New findings reshape how we view blood markers in CKD and cardiovascular risk When researchers at the University of Texas at Arlington set out to understand why people with chronic kidney disease (CKD) often die from heart problems rather than kidney failure, they revisited a long-standing assumption about blood markers. For years, scientists highlighted ADMA…
-
Inactive SDMA Emerges as Potential Predictor of Cardiovascular Risk in CKD
New Findings Reframe SDMA’s Role in CKD-Related Cardiovascular Risk When researchers at the University of Texas at Arlington set out to understand why people with chronic kidney disease (CKD) are at heightened risk for heart problems, they revisited a long-standing assumption. For years, ADMA—asymmetric dimethylarginine—has been considered a warning sign for vascular dysfunction. But a…